A Phase IIA Randomised, Double-blind, Double Dummy, Placebo and Active Controlled 5-Way Cross-over Trial to Examine the Bronchodilator Effects of PF-610,355 and to Test for Superiority Versus Placebo in Reversible Asthmatic Patients.
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2014
At a glance
- Drugs PF 610355 (Primary) ; Salmeterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Pfizer
- 15 Sep 2009 Results presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009).
- 30 Nov 2007 Status changed from in progress to completed.
- 14 Nov 2007 Status changed from recruiting to in progress.